HUTCHMED (NASDAQ:HCM) announced Wednesday the initiation of a Phase I/IIa clinical trial for HMPL-A580, marking the first human testing of its second antibody-targeted therapy conjugate (ATTC) for the treatment of solid tumors.
The multicenter, open-label study is being conducted across clinical sites in both the United States and China.
HMPL-A580 is designed as a precision oncology agent that combines an anti-EGFR antibody with a PI3K/PIKK inhibitor payload.
The dual-mechanism approach seeks to deliver a potent signaling inhibitor directly to cancer cells overexpressing the EGFR protein, potentially limiting systemic exposure and enhancing the therapeutic window.
The clinical program (ClinicalTrials.gov identifier NCT07396584) is structured to evaluate the safety, tolerability, and pharmacokinetics of the compound.
The initial Phase I portion of the study will focus on dose-escalation to determine the maximum tolerated dose and the recommended Phase II dose.
This will be followed by a Phase IIa expansion phase, which aims to further characterize the drug's preliminary efficacy, immunogenicity, and anti-tumor activity in specific patient populations.
The transition of HMPL-A580 into the clinic represents a significant expansion of HUTCHMED’s proprietary ATTC platform.
By utilizing antibodies to transport small-molecule inhibitors rather than traditional cytotoxic chemotherapy, the company is attempting to differentiate its pipeline from standard antibody-drug conjugates (ADCs).
HUTCHMED noted that the global nature of the study facilitates a diverse patient enrollment as it seeks to address unmet needs in solid tumor malignancies.